Jubilee Brown to Female
This is a "connection" page, showing publications Jubilee Brown has written about Female.
Connection Strength
0.628
-
Brown J, Miller A, Holman LL, Backes F, Nagel C, Bender D, Miller DS, Powell MA, Westin SN, Bonebrake A, Muller CY, Secord AA, Crane E, Schorge J, Tew WP, Sood AK, Bookman MA, Aghajanian C, Gershenson DM. Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14. Gynecol Oncol. 2024 Nov; 190:283-290.
Score: 0.063
-
ElNaggar A, Robins D, Baca Y, Arguello D, Ulm M, Arend R, Mantia-Smaldone G, Chu C, Winer I, Holloway R, Krivak T, Jones N, Galvan-Turner V, Herzog TJ, Brown J. Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy. Gynecol Oncol. 2022 Nov; 167(2):306-313.
Score: 0.056
-
Lees B, Brown J. Evaluation and Management of Common Intraoperative and Postoperative Complications in Gynecologic Endoscopy. Obstet Gynecol Clin North Am. 2022 Jun; 49(2):355-368.
Score: 0.054
-
Shushkevich A, Thaker PH, Littell RD, Shah NA, Chiang S, Thornton K, Hensley ML, Slomovitz BM, Holcomb KM, Leitao MM, Toboni MD, Powell MA, Levine DA, Dowdy SC, Klopp A, Brown J. State of the science: Uterine sarcomas: From pathology to practice. Gynecol Oncol. 2020 Oct; 159(1):3-7.
Score: 0.048
-
Brown J, Drury L, Raub K, Levy B, Brantner P, Krivak TC, Bradley L, Naumann RW. Workplace Harassment and Discrimination in Gynecology: Results of the AAGL Member Survey. J Minim Invasive Gynecol. 2019; 26(5):838-846.
Score: 0.043
-
Naumann RW, Morris JC, Tait DL, Higgins RV, Crane EK, Drury LK, Amacker-North L, Templin M, Brown J. Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer. Gynecol Oncol. 2018 Dec; 151(3):477-480.
Score: 0.042
-
Shiffman M, Da B, Goel A, Kwong A, Stein L, Moreno C, Nicoll A, Mehta A, Louvet A, Flamm S, Pyrsopoulos N, Satapathy S, Kuo A, Ganger D, Aloman C, Strasser SI, Tse E, Russo MW, Rockey D, Gray M, Mitchell M, Thursz M, Krebs W, Scott D, Blevins C, Ellis D, Brown J, Sussman N, Lin W. Larsucosterol for the Treatment of Alcohol-Associated Hepatitis. NEJM Evid. 2025 Feb; 4(2):EVIDoa2400243.
Score: 0.016
-
Wilhite AM, Wu S, Xiu J, Gibney GT, Phung T, In GK, Herzog TJ, Khabele D, Erickson BK, Brown J, Rocconi RP, Pierce JY, Scalici JM, Jones NL. A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma. Gynecol Oncol. 2024 Sep; 188:13-21.
Score: 0.016
-
Gupta A, Thompson JC, Ringel NE, Kim-Fine S, Ferguson LA, Blank SV, Iglesia CB, Balk EM, Secord AA, Hines JF, Brown J, Grimes CL. Sexual Harassment, Abuse, and Discrimination in Obstetrics and Gynecology: A Systematic Review. JAMA Netw Open. 2024 May 01; 7(5):e2410706.
Score: 0.015
-
André T, Berton D, Curigliano G, Sabatier R, Tinker AV, Oaknin A, Ellard S, de Braud F, Arkenau HT, Trigo J, Gravina A, Kristeleit R, Moreno V, Abdeddaim C, Vano YA, Samouëlian V, Miller R, Boni V, Torres AA, Gilbert L, Brown J, Dewal N, Dabrowski C, Antony G, Zografos E, Veneris J, Banerjee S. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial. JAMA Netw Open. 2023 Nov 01; 6(11):e2341165.
Score: 0.015
-
Grisham RN, Slomovitz BM, Andrews N, Banerjee S, Brown J, Carey MS, Chui H, Coleman RL, Fader AN, Gaillard S, Gourley C, Sood AK, Monk BJ, Moore KN, Ray-Coquard I, Shih IM, Westin SN, Wong KK, Gershenson DM. Low-grade serous ovarian cancer: expert consensus report on the state of the science. Int J Gynecol Cancer. 2023 Sep 04; 33(9):1331-1344.
Score: 0.015
-
Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, Sabatier R, O'Malley DM, Samouelian V, Boni V, Duska L, Ghamande S, Ghatage P, Kristeleit R, Leath C, Dong Y, Veneris J, Pothuri B. A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer. Future Oncol. 2023 Aug; 19(25):1709-1714.
Score: 0.015
-
Levytska K, Pena SR, Brown J, Yu Z, Wally MK, Hsu JR, Seymour RB, Naumann W. Opioid and benzodiazepine use in gynecologic oncology patients. Int J Gynecol Cancer. 2023 May 01; 33(5):786-791.
Score: 0.014
-
Klc TR, Wu S, Wilhite AM, Jones NL, Powell MA, Olawaiye A, Girda E, Brown J, Puechl A, Ali-Fehmi R, Winer IS, Herzog TJ, Korn WM, Erickson BK. HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy. Gynecol Oncol. 2022 Nov; 167(2):289-294.
Score: 0.014
-
Lees BF, Johnson S, Donahue E, Bose R, Brown J, Crane E, Puechl A, Tait D, Naumann RW. Improved Rates of Same-day Discharge in Patients Undergoing Surgery for Endometrial Cancer Following the COVID-19 Pandemic. J Minim Invasive Gynecol. 2022 Nov; 29(11):1248-1252.
Score: 0.014
-
Leitao MM, Zhou QC, Brandt B, Iasonos A, Sioulas V, Lavigne Mager K, Shahin M, Bruce S, Black DR, Kay CG, Gandhi M, Qayyum M, Scalici J, Jones NL, Paladugu R, Brown J, Naumann RW, Levine MD, Mendivil A, Lim PC, Kang E, Cantrell LA, Sullivan MW, Martino MA, Kratz MK, Kolev V, Tomita S, Leath CA, Boitano TKL, Doo DW, Feltmate C, Sugrue R, Olawaiye AB, Goldfeld E, Ferguson SE, Suhner J, Abu-Rustum NR. The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes. Gynecol Oncol. 2022 Sep; 166(3):417-424.
Score: 0.014
-
Levytska K, Yu Z, Wally M, Odum S, Hsu JR, Seymour R, Brown J, Crane EK, Tait DL, Puechl AM, Lees B, Naumann RW. Enhanced recovery after surgery (ERAS) protocol is associated with lower post-operative opioid use and a reduced office burden after minimally invasive surgery. Gynecol Oncol. 2022 Sep; 166(3):471-475.
Score: 0.014
-
Wilhite AM, Baca Y, Xiu J, Paladugu R, ElNaggar AC, Brown J, Winer IS, Morris R, Erickson BK, Olawaiye AB, Powell M, Korn WM, Rocconi RP, Khabele D, Jones NL. Molecular profiles of endometrial cancer tumors among Black patients. Gynecol Oncol. 2022 Jul; 166(1):108-116.
Score: 0.013
-
Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, Sabatier R, O'Malley DM, Samouelian V, Boni V, Duska L, Ghamande S, Ghatage P, Kristeleit R, Leath C III, Guo W, Im E, Zildjian S, Han X, Duan T, Veneris J, Pothuri B. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022 Jan; 10(1).
Score: 0.013
-
Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, Barretina-Ginesta MP, Moreno V, Gravina A, Abdeddaim C, Banerjee S, Guo W, Danaee H, Im E, Sabatier R. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer. Future Oncol. 2021 Oct 01; 17(29):3781-3785.
Score: 0.013
-
Brancazio SN, Lehman A, Kemp EV, Brown J, Crane EK, Tait DL, Taylor VD, Naumann RW. Factors Associated with Same Day Discharge after Laparoscopic Surgery in Gynecologic Oncology. J Minim Invasive Gynecol. 2022 Jan; 29(1):114-118.
Score: 0.013
-
Toboni MD, Crane EK, Brown J, Shushkevich A, Chiang S, Slomovitz BM, Levine DA, Dowdy SC, Klopp A, Powell MA, Thaker PH. Uterine carcinosarcomas: From pathology to practice. Gynecol Oncol. 2021 Jul; 162(1):235-241.
Score: 0.013
-
Crane EK, Brown J, Lehman A, Tait DL, Naumann RW. Perioperative Recovery and Narcotic Use in Laparoscopic versus Robotic Surgery for Endometrial Cancer. J Minim Invasive Gynecol. 2021 Nov; 28(11):1898-1902.
Score: 0.013
-
Naumann RW, Hughes BN, Brown J, Drury LK, Herzog TJ. The impact of opportunistic salpingectomy on ovarian cancer mortality and healthcare costs: a call for universal insurance coverage. Am J Obstet Gynecol. 2021 Oct; 225(4):397.e1-397.e6.
Score: 0.012
-
Tait DL, Lehman A, Brown J, Crane EK, Kemp EV, Taylor VD, Naumann RW. Comparison of Perioperative Outcomes between Minimally Invasive Sentinel Node Biopsy and Full Lymphadenectomy for Endometrial Cancer. J Minim Invasive Gynecol. 2021 Aug; 28(8):1514-1518.
Score: 0.012
-
Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, Barretina-Ginesta MP, Moreno V, Gravina A, Abdeddaim C, Banerjee S, Guo W, Danaee H, Im E, Sabatier R. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial. JAMA Oncol. 2020 Nov 01; 6(11):1766-1772.
Score: 0.012
-
Levine MD, Brown J, Crane EK, Tait DL, Naumann RW. Outcomes of Minimally Invasive versus Open Radical Hysterectomy for Early Stage Cervical Cancer Incorporating 2018 FIGO Staging. J Minim Invasive Gynecol. 2021 Apr; 28(4):824-828.
Score: 0.012
-
Lehman A, Kemp EV, Brown J, Crane EK, Tait DL, Taylor VD, Naumann RW. Pre-emptive Non-narcotic Pain Medication before Minimally Invasive Surgery in Gynecologic Oncology. J Minim Invasive Gynecol. 2021 Apr; 28(4):811-816.
Score: 0.012
-
Fader AN, Huh WK, Kesterson J, Pothuri B, Wethington S, Wright JD, Bakkum-Gamez JN, Soliman PT, Sinno AK, Leitao M, Martino MA, Karam A, Rossi E, Brown J, Blank S, Burke W, Goff B, Yamada SD, Uppal S, Dowdy SC. When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic. Gynecol Oncol. 2020 Aug; 158(2):236-243.
Score: 0.012
-
Naumann RW, Coleman RL, Brown J, Moore KN. Phase III trials in ovarian cancer: The evolving landscape of front line therapy. Gynecol Oncol. 2019 May; 153(2):436-444.
Score: 0.011